Equities research analysts at Morgan Stanley initiated coverage on shares of Embecta (NASDAQ:EMBC – Get Rating) in a report released on Monday, MarketBeat.com reports. The firm set an “equal weight” rating and a $33.00 price target on the stock. Morgan Stanley’s target price would suggest a potential upside of 9.05% from the stock’s current price.
Separately, Bank of America initiated coverage on Embecta in a research report on Tuesday, June 21st. They set an “underperform” rating and a $25.00 target price on the stock.
Embecta Stock Performance
Shares of EMBC opened at $30.26 on Monday. The business’s 50 day moving average price is $26.76. Embecta has a 1 year low of $23.62 and a 1 year high of $49.00.
About Embecta
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally.
Recommended Stories
- Get a free copy of the StockNews.com research report on Embecta (EMBC)
- 3 Health Care Stocks in Great Financial Health
- Amazon Names Itself A Top Stock Of Q3 Contender
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Are Baidu’s Delisting Fears a Good Entry for New Investors?
- Pinterest Shares Are Soaring After Earnings, Is The Stock A Buy?
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Embecta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Embecta and related companies with MarketBeat.com's FREE daily email newsletter.
